Published in Endocr Relat Cancer on August 16, 2017
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Cancer statistics, 2016. CA Cancer J Clin (2016) 32.95
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet (1995) 6.60
Sex differences in autoimmune disease. Nat Immunol (2001) 5.08
Breakthrough of the year 2013. Cancer immunotherapy. Science (2013) 5.05
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med (2017) 4.48
Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell (2010) 4.16
T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A (2001) 3.15
Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials. Eur Urol (2013) 2.84
Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res (2011) 2.81
Studies of the regulatory effects of the sex hormones on antibody formation and stem cell differentiation. J Exp Med (1972) 2.44
Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell (2005) 2.37
Activation of thymic regeneration in mice and humans following androgen blockade. J Immunol (2005) 2.31
Influence of sex in immunoglobulin levels. Nature (1967) 2.25
Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse. Sci Transl Med (2016) 2.09
Systems analysis of sex differences reveals an immunosuppressive role for testosterone in the response to influenza vaccination. Proc Natl Acad Sci U S A (2013) 2.00
Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology (1999) 1.92
Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol Immunother (2012) 1.82
Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol (2004) 1.71
Testosterone replacement effectively inhibits the development of experimental autoimmune orchitis in rats: evidence for a direct role of testosterone on regulatory T cell expansion. J Immunol (2011) 1.65
An androgen receptor N-terminal domain antagonist for treating prostate cancer. J Clin Invest (2013) 1.64
Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Clin Cancer Res (2008) 1.60
Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer. J Urol (2005) 1.59
TWISTing an embryonic transcription factor into an oncoprotein. Oncogene (2010) 1.57
Androgen receptors in thymic epithelium modulate thymus size and thymocyte development. Endocrinology (2001) 1.53
The androgen receptor: a biologically relevant vaccine target for the treatment of prostate cancer. Cancer Immunol Immunother (2012) 1.50
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N Engl J Med (2017) 1.43
Testosterone acts directly on CD4+ T lymphocytes to increase IL-10 production. J Immunol (2001) 1.34
ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors. Neoplasia (2012) 1.28
Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions. Nucleic Acids Res (2012) 1.24
Steroidogenic enzymes and stem cell markers are upregulated during androgen deprivation in prostate cancer. Mol Med (2011) 1.24
Successive waves of apoptosis in the rat prostate after repeated withdrawal of testosterone stimulation. Pathology (1984) 1.23
Effect of medical castration on CD4+ CD25+ T cells, CD8+ T cell IFN-gamma expression, and NK cells: a physiological role for testosterone and/or its metabolites. Am J Physiol Endocrinol Metab (2005) 1.21
Enhanced immune system regeneration in humans following allogeneic or autologous hemopoietic stem cell transplantation by temporary sex steroid blockade. Clin Cancer Res (2008) 1.20
Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization. Prostate (2009) 1.19
Estrogen receptor profiles in human peripheral blood lymphocytes. Immunol Lett (2010) 1.19
Sex-associated differences in the regulation of immune responses controlled by the MHC of the mouse. J Immunol (1984) 1.16
Oestrogen and human T lymphocytes: presence of specific receptors in the T-suppressor/cytotoxic subset. Scand J Immunol (1988) 1.16
Combination therapy with a second-generation androgen receptor antagonist and a metastasis vaccine improves survival in a spontaneous prostate cancer model. Clin Cancer Res (2013) 1.15
Oestradiol potentiates the suppressive function of human CD4 CD25 regulatory T cells by promoting their proliferation. Immunology (2006) 1.14
Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses. Hum Immunol (2010) 1.08
Effects of androgens on T and B lymphocyte development. Immunol Res (2001) 1.07
Ligand-independent activation of androgen receptors by Rho GTPase signaling in prostate cancer. Mol Endocrinol (2007) 1.04
Inhibition of androgen-independent prostate cancer by estrogenic compounds is associated with increased expression of immune-related genes. Neoplasia (2006) 1.02
Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer. J Med Chem (2015) 1.02
The effect of testosterone replacement treatment on immunological features of patients with Klinefelter's syndrome. Clin Exp Immunol (2000) 1.01
Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor. Clin Cancer Res (2014) 1.00
Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway. Oncotarget (2014) 1.00
A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res (2015) 0.98
Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget (2016) 0.97
Lobe-specific apoptotic cell death in rat prostate after androgen ablation by castration. Endocrinology (1995) 0.96
Androgens alter T-cell immunity by inhibiting T-helper 1 differentiation. Proc Natl Acad Sci U S A (2014) 0.95
Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer. Cancer Immunol Immunother (2011) 0.93
High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer. Eur J Cancer (2012) 0.92
Androgen ablation augments human HLA2.1-restricted T cell responses to PSA self-antigen in transgenic mice. Prostate (2010) 0.91
In situ vaccination combined with androgen ablation and regulatory T-cell depletion reduces castration-resistant tumor burden in prostate-specific pten knockout mice. Cancer Res (2010) 0.91
Increased CD8+ T-cell function following castration and immunization is countered by parallel expansion of regulatory T cells. Cancer Res (2012) 0.91
PSA progression following radical prostatectomy and radiation therapy: new standards in the new Millennium. Eur Urol (2003) 0.91
Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. J Clin Oncol (2016) 0.91
Evidence that androgens modulate human thymic T cell output. J Investig Med (2011) 0.88
Androgen receptor modulates Foxp3 expression in CD4+CD25+Foxp3+ regulatory T-cells. Mol Biol Cell (2015) 0.88
Androgen receptor gene mutation, rearrangement, polymorphism. Transl Androl Urol (2013) 0.87
Sex steroid blockade enhances thymopoiesis by modulating Notch signaling. J Exp Med (2014) 0.86
Estradiol-dependent perforin expression by human regulatory T-cells. Eur J Clin Invest (2010) 0.84
Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer. Endocr Relat Cancer (2015) 0.82
Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically-Recurrent Prostate Cancer: A Phase II Randomized Trial. Clin Cancer Res (2016) 0.81
T cells localized to the androgen-deprived prostate are TH1 and TH17 biased. Prostate (2011) 0.80
EPI-001, A Compound Active against Castration-Resistant Prostate Cancer, Targets Transactivation Unit 5 of the Androgen Receptor. ACS Chem Biol (2016) 0.80
Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer. Oncologist (2016) 0.80
Goserelin versus leuprolide in the chemical castration of patients with prostate cancer. Int Urol Nephrol (2012) 0.79
The Influence of Dihydrotestosterone on the Development of Graves' Disease in Female BALB/c Mice. Thyroid (2016) 0.78
Lymphocyte subsets in patients with oestrogen deficiency. J Reprod Immunol (1991) 0.78
Androgens suppress antigen-specific T cell responses and IFN-γ production during intracranial LCMV infection. J Neuroimmunol (2010) 0.78
Influence of Testosterone on Inflammatory Response in Testicular Cells and Expression of Transcription Factor Foxp3 in T Cells. Am J Reprod Immunol (2015) 0.77
Sponging off nature for new drug leads. Biochem Pharmacol (2017) 0.77
Intermittent androgen deprivation therapy in advanced prostate cancer. Curr Treat Options Oncol (2014) 0.76
Urological cancer: CHAARTED/GETUG 12-docetaxel in non-castrate prostate cancers. Nat Rev Clin Oncol (2015) 0.76
Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study. Prostate (2016) 0.76